Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BIRB-796 + Dasatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BIRB-796||Doramapimod|BIRB796|BIRB 796||p38 MAPK Inhibitor (Pan) 4||Doramapimod (BIRB-796) is an oral inhibitor of P38 MAPK that enhances cytotoxicity of other anti-tumor agents (PMID: 17173546, PMID: 27082306).|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 25 BTK inhibitor 22 CSF1R Inhibitor 23 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 50 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 29 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRC positive||triple-receptor negative breast cancer||sensitive||BIRB-796 + Dasatinib||Preclinical - Cell culture||Actionable||In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914).||27154914|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|